ARWR Share Price Performance
US$77.91
61.84 (384.82%)
21.6% overvalued intrinsic discount
US$64.08
Fair Value
Price US$77.91
AnalystConsensusTarget US$64.08
AnalystHighTarget US$110.00
AnalystLowTarget US$42.57
Fair ValueUS$64.08
Share Pricen/a
Arrowhead Pharmaceuticals, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 17 Fair Values set on narratives written by author
ARWR Community Narratives
AN
Fair Value
·Fair Value US$64.08 21.6% overvalued intrinsic discount
Analysts Boost Arrowhead Pharmaceuticals Price Target Amid Cost Advantages and Strategic Partnerships
0users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
AN
Fair Value
·Fair Value US$110 29.2% undervalued intrinsic discount
Advanced RNAi Launches Will Harness Demographic And Health Trends
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value US$42.57 83.0% overvalued intrinsic discount
Rising Healthcare Costs And Patent Expiry Will Crush RNAi Prospects
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Advanced RNAi Launches Will Harness Demographic And Health Trends
Arrowhead Pharmaceuticals is pushing RNA-based medicines toward launch, and faster trial progress plus big pharma deals could bring in cash sooner than many expect. But the story hinges on expensive late-stage trials and a small set of programs, so setbacks, tougher competition, or drug-pricing pressure could quickly change the outlook.Read more
AN
US$110
29.2% undervalued intrinsic discount
Fair Value
Profit Margin
14.57%
Future PE
119.46x
Price in 2029
US$135.11
Rising Healthcare Costs And Patent Expiry Will Crush RNAi Prospects
Key Takeaways Growth is threatened by stricter reimbursement, increased competition from generics and new gene-editing technologies, and potential regulatory headwinds for novel therapies. Heavy dependence on RNAi drugs, a few key pipeline assets, and external partners heightens risks around revenue stability and long-term profitability.Read more
AN
US$42.57
83.0% overvalued intrinsic discount
Fair Value
Revenue
-32.78% p.a.
Profit Margin
14.83%
Future PE
155.07x
Price in 2029
US$52.18
Analysts Boost Arrowhead Pharmaceuticals Price Target Amid Cost Advantages and Strategic Partnerships
Key Takeaways Advancing RNAi therapy pipeline and global partnerships boost Arrowhead's growth prospects, competitive position, and access to emerging healthcare markets. Strategic collaborations and favorable regulatory trends support revenue stability, strong margins, and opportunities for long-term earnings and expansion.Read more
AN
US$64.08
21.6% overvalued intrinsic discount
Fair Value
Profit Margin
16.03%
Future PE
168.04x
Price in 2028
US$78.72
Trending Discussion
Recently Updated Narratives
AN
ARWR: Cardiometabolic RNAi Data And Licensing Will Drive Future Repricing
Fair Value: US$110 29.2% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ARWR: Wave Data Concerns Will Test Sustainability Of Recent Share Price Rebound
Fair Value: US$42.57 83.0% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ARWR: Upcoming SHTG Readouts Will Temper Optimism Despite Recent Cardiometabolic Progress
Fair Value: US$64.08 21.6% overvalued intrinsic discount
13 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Arrowhead Pharmaceuticals, Inc. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
- -2.14
- 100.00%
- -48.38%
- 213.0%
About ARWR
- Founded
- 2003
- Employees
- 711
- CEO
- WebsiteView website
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
